Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives

Chemical Biology and Drug Design

Volumn 78, Issue 6, 2011, Pages 932-940

  Wu, Xiaoqing ^a,b   Li, Mingdong ^a   Tang, Wenhua ^b   Zheng, Youguang ^a   Lian, Jiqin ^b   Xu, Liang ^b   Ji, Min ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

4 pyrrylamino quinazoline; Antitumor activity; Cancer cells; Gefitinib; Receptor tyrosine kinase

Indexed keywords

4 PYRRYLAMINO QUINAZOLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETHYL 3 [6 [3 (DIETHYLAMINO)PROPOXY] 7 METHOXYQUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (2 METHYLPIPERIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (4 ETHYLPIPERAZIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (4 METHYLPIPERAZIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (4 METHYLPIPERIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (4 PHENYLPIPERAZIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (PIPERIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [6 METHOXY 7 [3 (PYRROLIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 [3 (DIETHYLAMINO)PROPOXY] 6 METHOXYQUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 (3 MORPHOLINOPROPOXY)QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (2 METHYLPIPERIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (4 ETHYLPIPERAZIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (4 METHYLPIPERAZIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (4 METHYLPIPERIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (4 PHENYLPIPERAZIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (PIPERIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; ETHYL 3 [7 METHOXY 6 [3 (PYRROLIDIN 1 YL)PROPOXY]QUINAZOLIN 4 YLAMINO] 1H PYRROLE 2 CARBOXYLATE; GEFITINIB; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DESIGN; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 81355146363     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01234.x     Document Type: Article

References (17)

1. Gschwind A., Fischer O.M., Ullrich A. (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer;4:361-370.
2. Zwick E., Bange J., Ullrich A. (2002) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med;8:17-23.
3. Brunelleschi S., Penengo L., Santoro M.M., Gaudino G. (2002) Receptor tyrosine kinases as target for anti-cancer therapy. Curr Pharm Des;8:1959-1972.
4. Cohen M.H., Williams G.A., Sridhara R., Chen G., Pazdur R. (2003) FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist;8:303-306.
5. Cohen M.H., Johnson J.R., Chen Y.F., Sridhara R., Pazdur R. (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist;10:461-466.
6. Ryan Q., Ibrahim A., Cohen M.H., Johnson J., Ko C.W., Sridhara R., Justice R., Pazdur R. (2008) FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist;13:1114-1119.
7. Wu X., Li M., Qu Y., Tang W., Zheng Y., Lian J., Ji M., Xu L. (2010) Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. Bioorg Med Chem;18:3812-3822.
8. Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H.R., Cody D.R., Mcmichael A., Fry D.W. (1995) Tyrosine kinase inhibitors. 5. Synthesis and structure-activity-relationships for 4-[(Phenylmethyl)Amino]-quinazolines and 4-(Phenylamino)quinazolines as potent adenosine 5′-triphosphate binding-site inhibitors of the tyrosine kinase domain of the epidermal growth-factor receptor. J Med Chem;38:3482-3487.
9. Bridges A.J., Zhou H., Cody D.R., Rewcastle G.W., McMichael A., Showalter H.D.H., Fry D.W., Kraker A.J., Denny W.A. (1996) Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6, 7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem;39:267-276.
10. Smaill J.B., Palmer B.D., Rewcastle G.W., Denny W.A., McNamara D.J., Dobrusin E.M., Bridges A.J., et al. (1999) Tyrosine kinase inhibitors. 15. 4-(phenylamino)quinazoline and 4-(phenylamino)pyrido[d] pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem;42:1803-1815.
11. Smaill J.B., Rewcastle G.W., Loo J.A., Greis K.D., Chan O.H., Reyner E.L., Lipka E., Showalter H.D., Vincent P.W., Elliott W.L., Denny W.A. (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]-pyrimidine-6-acrylamides bearing additional solubilizing functions (vol 43, pg 1380, 2000). J Med Chem;43:3180-1397.
12. Wissner A., Berger D.M., Boschelli D.H., Floyd M.B. Jr, Greenberger L.M., Gruber B.C., Johnson B.D., et al. (2000) 4-Anilino-6, 7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6, 7-dialkoxyquinazoline inhibitors. J Med Chem;43:3244-3256.
13. Assefa H., Kamath S., Buolamwini J.K. (2003) 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. J Comput Aided Mol Des;17:475-493.
14. Zhang Y.M., Cockerill S., Guntrip S.B., Rusnak D., Smith K., Vanderwall D., Wood E., Lackey K. (2004) Synthesis and SAR of potent EGFR/erbB2 dual inhibitors. Bioorg Med Chem Lett;14:111-114.
15. Petrov K.G., Zhang Y.M., Carter M., Cockerill G.S., Dickerson S., Gauthier C.A., Guo Y., Mook R.A. Jr, Rusnak D.W., Walker A.L., Wood E.R., Lackey K.E. (2006) Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series. Bioorg Med Chem Lett;16:4686-4691.
16. Ballard P., Bradbury R.H., Harris C.S., Hennequin L.F., Hickinson M., Kettle J.G., Kendrew J., Klinowska T., Ogilvie D.J., Pearson S.E., Williams E.J., Wilson I. (2006) Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. Bioorg Med Chem Lett;16:4908-4912.
17. Zheng Y.G., Wu X.Q., Sun M., Feng L.H., Li M.D., Ji M. (2009) Design, synthesis, crystal structure and antitumor activity of a new ethyl 3-(quinazolin-4-ylamino)-1H-pyrrole-2-carboxylate derivative. Lett Drug Des Discov;6:538-541.